Imcyse closes €21.3m Series B as new partner Pfizer takes equity stake
Belgium-based Imcyse has closed a €21.3m ($25.8m) Series B round. Investors participating in the round included Société Fédérale de Participations…
03 Feb 2021
TCR-T cell therapies for cancer: TScan raises $100m in Series C round
Massachusetts-based TScan Therapeutics has closed an oversubscribed $100m Series C round. This financing attracted both new and existing investors. New investors that participated were BlackRock and RA Capital, while existing…
13 Jan 2021
Disease-cancelling drugs: Immuneering raises $62m in Series B round
Massachusetts-based Immuneering Corporation has closed an oversubscribed $62m Series B round. The financing was led by Cormorant Asset Management. Surveyor Capital, Rock Springs Capital, as well as funds and accounts…
11 Dec 2020
Spotlight on rare neurological diseases: Noema closes $60.8m Series A round
Swiss-based Noema Pharma has raised CHF54m ($60.8m) in an oversubscribed Series A round. The funding was co-led by Sofinnova Partners and Polaris Partners; other investors included Gilde Healthcare and BioMed…
08 Dec 2020
Investing in innovative biotechs with Novo Ventures
Founded in the 1990s, the Novo Nordisk Foundation oversees the management and administration of the Novo Group, comprised of Novo Nordisk, the Danish pharma giant renowned for its diabetes research and products,…
02 Dec 2020
SynOx raises €37m in Series A to develop emactuzumab for rare cancer TGCT
Dublin-based biopharma company SynOx has secured €37m in a Series A financing round led by HealthCap and Medicxi. Forbion and Gimv also participated in the financing. SynOx is a single…
02 Nov 2020
Araris raises CHF15.2m to support its next-gen ADCs
Switzerland-based Araris Biotech has raised CHF15.2m ($16.6m) in a seed financing round. The round was led by Pureos Bioventures and two new investors, 4BIO Capital and btov Partners. Three existing…